MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...
After 10 weeks of training at IMG Academy in Florida, 13 athletes from the International Player Pathway program will take the field for a workout in front of NFL scouts. IPP consultant Scott Pioli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback